Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.

Chase DM, Herrstedt J, Miller EM, Gilbert L, Zub O, Mathews C, Angioli R, Teneriello M, Gropp-Meier M, Powell MA, Reyners AKL, Cloven NG, Eminowicz G, Gill SE, Maćkowiak-Matejczyk B, Pothuri B, Samouëlian V, Jain A, Boone J, Bouberhan S, Trinidad J, Braly P, Buttin B, Backes FJ, Sawyer B, Antony G, Garside J, Allonby O, McCourt CK, Mirza MR

Open source

DOI: 10.1016/j.ijgc.2025.101935
Published: 2025 Aug
Container: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ijgc.2025.101935,
  title = {Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.},
  author = {Chase DM and Herrstedt J and Miller EM and Gilbert L and Zub O and Mathews C and Angioli R and Teneriello M and Gropp-Meier M and Powell MA and Reyners AKL and Cloven NG and Eminowicz G and Gill SE and Maćkowiak-Matejczyk B and Pothuri B and Samouëlian V and Jain A and Boone J and Bouberhan S and Trinidad J and Braly P and Buttin B and Backes FJ and Sawyer B and Antony G and Garside J and Allonby O and McCourt CK and Mirza MR},
  year = {2025},
  journal = {International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  doi = {10.1016/j.ijgc.2025.101935},
  url = {https://doi.org/10.1016/j.ijgc.2025.101935}
}

RIS

TY  - JOUR
TI  - Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
AU  - Chase DM
AU  - Herrstedt J
AU  - Miller EM
AU  - Gilbert L
AU  - Zub O
AU  - Mathews C
AU  - Angioli R
AU  - Teneriello M
AU  - Gropp-Meier M
AU  - Powell MA
AU  - Reyners AKL
AU  - Cloven NG
AU  - Eminowicz G
AU  - Gill SE
AU  - Maćkowiak-Matejczyk B
AU  - Pothuri B
AU  - Samouëlian V
AU  - Jain A
AU  - Boone J
AU  - Bouberhan S
AU  - Trinidad J
AU  - Braly P
AU  - Buttin B
AU  - Backes FJ
AU  - Sawyer B
AU  - Antony G
AU  - Garside J
AU  - Allonby O
AU  - McCourt CK
AU  - Mirza MR
PY  - 2025
JO  - International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
DO  - 10.1016/j.ijgc.2025.101935
UR  - https://doi.org/10.1016/j.ijgc.2025.101935
ER  -

APA

DM, C., J, H., EM, M., L, G., O, Z., C, M., R, A., M, T., M, G., MA, P., AKL, R., NG, C., G, E., SE, G., B, M., B, P., V, S., A, J., J, B., S, B., J, T., P, B., B, B., FJ, B., B, S., G, A., J, G., O, A., CK, M., & MR, M. (2025). Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. https://doi.org/10.1016/j.ijgc.2025.101935

Source records

pubmed · retrieved 2026-09-25T15:24:22.539Z